<DOC>
	<DOCNO>NCT02009384</DOCNO>
	<brief_summary>This open-label , clinical efficacy study Ipilimumab patient Stage IIIC Stage IV melanoma recently treat Denileukin Diftitox . Approximately 42 patient radiographically measurable melanoma receive least one cycle Denileukin Diftitox enrol treat study .</brief_summary>
	<brief_title>Ipilimumab Administered Stage IIIC Stage IV Melanoma After Reg . T Cell Depletion With Denileukin Diftitox</brief_title>
	<detailed_description>This open-label , clinical efficacy study Ipilimumab patient Stage IIIC Stage IV melanoma recently treat Denileukin Diftitox . Approximately 42 patient radiographically measurable melanoma receive least one cycle Denileukin Diftitox enrol treat study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female patient ≥18 year age ; 2 . Patients histological confirm melanoma ( Stage IIIC Stage IV , American Joint Commission Cancer ) ; 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 2 ; 4 . Life expectancy ≥3 month ; 5 . Treatment Denileukin Diftitox within 42 day prior first dose Ipilimumab ; 6 . At least 1 site radiographically measurable disease immunerelated response criterion ( irRC ) ; 7 . Adequate hematologic , renal , liver function define laboratory value perform within 42 day prior initiation dosing : Absolute neutrophil count ( ANC ) ≥1.0 x 109/L ; Platelet count ≥100 x 109/L ; Hemoglobin ≥8 g/dL ; Serum creatinine ≤3 x upper limit normal ( ULN ) Total serum bilirubin ≤2 x ULN ; Serum aspartate transaminase ( AST/SGOT ) serum alanine transaminase ( ALT/SGPT ) ≤2x ULN , ≤3 x ULN liver metastases present . 8 . Fertile male use effective method contraception treatment least 3 month completion treatment , direct physician ; 9 . Premenopausal females female &lt; 2 year onset menopause negative pregnancy test Screening . Premenopausal females must agree use acceptable method birth control time negative pregnancy test 90 day last dose study drug . Females nonchildbearing potential may include either surgically sterile postmenopausal ≥1 year ; 10 . Before study entry , write informed consent must obtain patient prior perform studyrelated procedure . 1 . Prior treatment Ipilimumab ; 2 . Known hypersensitivity Ipilimumab component ; 3 . Steroids within one week prior initiation Ipilimumab . 4 . Preexisting autoimmune colitis . 5 . Patients allograft require immunosuppression ; 6 . Known positive human immunodeficiency virus ( HIV ) 7 . Pregnant , breastfeeding , refuse double barrier contraception , oral contraceptive , avoidance pregnancy measure ; 8 . Have uncontrolled infection medical condition could interfere conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>